Advanced melanoma patients treated with an experimental pill developed by Roche and Daiichi Sankyo were 63 percent less likely to die than patients given chemotherapy, according to a new trial. The drug, vemurafenib, is designed for use in patients with tumors that have a mutation in a gene known as BRAF. About half of all melanomas -- the deadliest form of skin cancer -- have the genetic aberration.